Naked DNA vaccines come of age
Article Abstract:
Vical, the Naval Medical Research Center, and Pasteur Merieux Connaught have undertaken a study of a vaccine for malaria using "naked DNA," DNA which is delivered to the body without such vehicles as liposomes or virus vectors. The goal of this study was to ascertain the safety of immunization of DNA alone in humans and to see if DNA injected by itself would marshal cytotoxic T lymphocytes (CTLs) to kill intracellular parasites. The study found that direct intracmuscular injection of naked DNA evoked a dose-dependent CTL response in 11 of 17 healthy human volunteers. A scientist stated that DNA vaccines would work well in combating viral diseases where other live vaccines have failed or are too dangerous.
Comment:
Vical, the Naval Medical Research Center, and Pasteur Merieux Connaught have undertaken a study of a vaccine for malaria using "naked DNA," DNA which is delivered to the body without such vehicles as liposomes or virus vectors.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
BMS cancer spin-off raises first finance
Article Abstract:
Seattle Genetics of Bothell, WA, has secured $7 million in first-round financing from three investor groups, Olympic Venture Partners, Sofinnova Venture Partners and Indosuez Ventures. The company, which was formed by two engineers from Bristol-Myers Squibb, plans to raise an additional $10 million to $15 million in a second round of financing. The company currently has four anticancer drugs under development which will be used to treat such maladies as breast cancer, colon cancer and lung cancer.
Comment:
Seattle Genetics has secured $7 million in first-round financing from three investor groups
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Stem cell transformations proliferation
Article Abstract:
StemCell, a biotech company from Fremont, CA, is planning to market its new stem cell technique but Angelo Vescovi, one of its scientists, doubt the ability of stem cells to differentiate into other cell types.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Imaging comes of age. Treading cautiously. Less than meets the eye
- Abstracts: The Ramada revolution: the birth of a service culture in a franchise organization. The 100% Satisfaction Guarantee: ensuring quality at Hampton Inn
- Abstracts: Service and returns, discretion guaranteed. Patience required for best returns. Bargain hunting
- Abstracts: Standard-setting's future direction is unclear. The reality of realisation: Refining the realisation concept will solve derivative and hedge accounting problems
- Abstracts: Pulling the plug on the big bath scam: FRS 12 aims to clean up accounting provisions. Financial Reporting Standard 12: Provisions, Contingent Liabilities and Contingent Assets